RxDoctor Payments Data

Judith Bateman, MD

Rheumatology · Bingham Farms, MINPI 1356431381

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 28 payments — averaging $37.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$247
  • Amgen$229
  • Johnson & Johnson$180
  • Pfizer$150
  • Novo Nordisk$125
  • Pacira Therapeutics, Inc.$32
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$90385%
  • Education$16015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,062 in reported general payments places this provider in the 35th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$131,570
Medicare patients
350
Services billed
4,732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept63$457,550
Humira(Cf) PenAdalimumab63$435,958
Xeljanz XrTofacitinib Citrate73$404,362
Enbrel MiniEtanercept25$178,214
HumiraAdalimumab11$152,624
Orencia ClickjectAbatacept25$141,034
Actemra ActpenTocilizumab29$130,954
XeljanzTofacitinib Citrate15$82,216
RinvoqUpadacitinib11$65,367
BenlystaBelimumab13$57,635
KevzaraSarilumab13$52,170
Hydroxychloroquine Sulfate448$25,508
MethotrexateMethotrexate Sodium281$10,981
Prednisone429$6,576
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen296$6,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$150$82,21615 claims
GSKBenlysta$16$57,63513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Bingham Farms

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →